English українська
  1. SumDU Repository

Browsing by Author Sriuranpong, V.


Showing results 1 to 3 of 3
Issue Year Title Author(s) Type Views Downloads
2021 Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer Rugo, H.S.; Pennella, E.J.; Gopalakrishnan, U.; Hernandez‑Bronchud, M.; Herson, J.; Koch, H.F.; Loganathan, S.; Deodhar, S.; Marwah, A.; Manikhas, A.; Bondarenko, I.; Mukhametshina, G.; Nemsadze, G.; Parra, J.D.; Abesamis‑Tiambeng, M.L.T.; Baramidze, K.; Akewanlop, C.; Vynnychenko, Ihor Oleksandrovych; Sriuranpong, V.; Mamillapalli, G.; Roy, S.; Ruiz, E.P.Ya.; Barve, A.; Fuentes‑Alburo, A.; Walle, C.F. Article 0 0
2023 KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC Ren, S.; Feng, J.; Ma, S.; Chen, H.; Ma, Z.; Huang, C.; Zhang, L.; He, J.; Wang, C.; Zhou, J.; Danchaivijitr, P.; Wang, C.-C.; Vynnychenko, Ihor Oleksandrovych; Wang, K.; Orlandi, F.; Sriuranpong, V.; Li, B.; Ge, J.; Dang, T.; Zhou, C. Article 1794 796
2020 Randomized, open-label phase III study of pembrolizumab (pembro) vs docetaxel (doce) in patients (pts) with previously treated NSCLC with PD-L1 tumour proportion score (TPS) ≥1%: KEYNOTE-033 Zhou, C.; Feng, S.; Ma, S.; Chen, H.; Ma, Z.; Huang, C.; Zhang, L.; He, J.; Wang, C.; Zhou, J.; Danchaivijtr, P.; Huang, H-C.; Vynnychenko, Ihor Oleksandrovych; Wang, K.; Orlandi, F.; Sriuranpong, V.; Li, B.; Ge, J.; Dang, T. Conference Papers 1963732892 112788198